drugset / Trial / NCT05406440
A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of elpipodect in participants with schizophrenia.
Timeline
- Start
- 2022-07-12
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-8189 | Small molecule | 60 mg | Oral |
| Subject | MK-8189 | Small molecule | 80 mg | Oral |